Monoclonal antibody · developed by Tonix Pharmaceuticals
TNX-1500 is an Fc-modified anti-DF154 monoclonal antibody. It is being studied in adult kidney transplant recipients, in a safety study of kidney transplant rejection and immunosuppression.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07204080 | Phase 2 | Kidney Transplant | Not yet recruiting | TNXP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ImmunosuppressionImmunosuppression After Kidney TransplantationKidney TransplantKidney Transplant Failure and Rejection
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNXP page.
See TNXP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNXP catalysts and pipeline →